Skip to content

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

Shannon L. Maude, Noelle V. Frey, Pamela A. Shaw, Richard Aplenc, David Maxwell Barrett, Nancy Bunin, Anne Chew, Vanessa E. Gonzalez, Zhaohui Zheng, Simon Francis Lacey, Yolanda D. Mahnke, Jan Joseph Melenhorst, Susan R. Rheingold, Angela Shen, David T. Teachey, Bruce L. Levine, Carl H. June, David L. Porter, Stephan A. Grupp

New England Journal of Medicine · 2014 · 5,510 citationsOpen access

No retraction on record in OpenAlex.Check Crossref now

Cite this paper

Maude, S. L., Frey, N. V., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., Mahnke, Y. D., Melenhorst, J. J., Rheingold, S. R., Shen, A., Teachey, D. T., Levine, B. L., June, C. H., Porter, D. L., & Grupp, S. A. (2014). Chimeric antigen receptor T cells for sustained remissions in leukemia. New England Journal of Medicine, 371(16), 1507–1517. https://doi.org/10.1056/nejmoa1407222

In text: (Maude et al., 2014)

Ask a question about this research

One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.

Abstract

BACKGROUND: Relapsed acute lymphoblastic leukemia (ALL) is difficult to treat despite the availability of aggressive therapies. Chimeric antigen receptor-modified T cells targeting CD19 may overcome many limitations of conventional therapies and induce remission in patients with refractory disease. METHODS: We infused autologous T cells transduced with a CD19-directed chimeric antigen receptor (CTL019) lentiviral vector in patients with relapsed or refractory ALL at doses of 0.76×10(6) to 20.6×10(6) CTL019 cells per kilogram of body weight. Patients were monitored for a response, toxic effects, and the expansion and persistence of circulating CTL019 T cells. RESULTS: A total of 30 children and adults received CTL019. Complete remission was achieved in 27 patients (90%), including 2 patients with blinatumomab-refractory disease and 15 who had undergone stem-cell transplantation. CTL019 cells proliferated in vivo and were detectable in the blood, bone marrow, and cerebrospinal fluid of patients who had a response. Sustained remission was achieved with a 6-month event-free survival rate of 67% (95% confidence interval [CI], 51 to 88) and an overall survival rate of 78% (95% CI, 65 to 95). At 6 months, the probability that a patient would have persistence of CTL019 was 68% (95% CI, 50 to 92) and the probability that a patient would have relapse-free B-cell aplasia was 73% (95% CI, 57 to 94). All the patients had the cytokine-release syndrome. Severe cytokine-release syndrome, which developed in 27% of the patients, was associated with a higher disease burden before infusion and was effectively treated with the anti-interleukin-6 receptor antibody tocilizumab. CONCLUSIONS: Chimeric antigen receptor-modified T-cell therapy against CD19 was effective in treating relapsed and refractory ALL. CTL019 was associated with a high remission rate, even among patients for whom stem-cell transplantation had failed, and durable remissions up to 24 months were observed. (Funded by Novartis and others; CART19 ClinicalTrials.gov numbers, NCT01626495 and NCT01029366.).

  1. Control of Regulatory T Cell Development by the Transcription Factor Foxp32003
  2. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma2017
  3. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia2018
  4. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma2018
  5. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity2009

Metadata from OpenAlex (CC0). Citations are generated from the published record.